Lumida
/BCAX
⌘K
Bicara Therapeutics Inc

Bicara Therapeutics Inc

BCAX
$27.76USD↑+0.58%+0.16 today

MARKET CAP

1.8B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$27 – $28

52W RANGE

$10
$31

AI Summary

Stalk
Sell NowMedium

BCAX is in Stage 3 distribution, characterized by a blow-off top and immediate rejection, with short-term momentum turned down under the 9/21 EMAs. The medium-term tradable stance is bearish, favoring sell-side interaction on rallies into the short-EMA zone, while the long-term uptrend remains intact above the 200 DMA. Key risks include a failure to sustain selling pressure and a reclaim of short-term EMAs, which would invalidate the bearish bias.

  • ↑Fisera delivered median overall survival of 21.3 months vs 6.7 months standard care
  • ↑$539.8 M cash balance provides funding through H1 2029
  • ↓Operating expenses jumped 45% YoY to $112.8 M, elevating leverage risk
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Bicara Therapeutics, Inc. (NASDAQ: BCAX) is a clinical-stage biopharmaceutical company leading innovations in oncology, particularly focusing on developing therapies for HPV-negative head and neck cancers. The company’s primary asset, Phytherafisp-alpha (Fisera), targets unmet medical needs through a dual mechanism approach, combining an EGFR-directed antibody with TGF-beta inhibition. Positioned within the growing oncology therapeutics market, Bicara aims to become a frontrunner as it progresses through its pivotal clinical trials.

Bull says

  • ↑Fisera delivered median overall survival of 21.3 months vs 6.7 months standard care
  • ↑$539.8 M cash balance provides funding through H1 2029
  • ↑FDA granted breakthrough therapy designation for Fisera
  • ↑Ongoing alternative dosing study to boost adherence and meet FDA requirements
  • ↑Targeting a $5 B head and neck cancer market by the 2030s
  • ↑Positive price momentum and strong institutional ownership support

Bear says

  • ↓Operating expenses jumped 45% YoY to $112.8 M, elevating leverage risk
  • ↓Negative earnings yield and weak profitability indicators signal value trap
  • ↓Interim analysis slated for mid-2027 could face data or timing delays
  • ↓Intensifying competition from larger oncology players may pressure market share
  • ↓Key funding and market acceptance hinge on pivotal trial outcomes
  • ↓High leverage and negative growth factors raise sustainability concerns

Investment themes with BCAX

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-11-2026bullish

Transcript signals

Bull points

  • This patient population has particularly poor outcomes with limited treatment options and represents the vast majority of patients in this setting.
  • With two years of follow-up, deep and durable responses were observed with a median duration of response of 21.7 months and a median overall survival of 21.3 months, more than doubling the overall survival observed with the standard of care pembrolizumab in HPV-negative patients.
  • Taken together, the data presented to date affirm that Vysera has the potential to be a well-tolerated, chemotherapy-free treatment option across the spectrum of disease burden, including in patients with large, bulky tumors and low CPS scores, where rapid and deep responses are particularly critical.

Bear points

  • Our total operating expenses for the first quarter of 2026 increased compared to our first quarter of 2025, driven by clinical operations and development expenses associated with our ongoing pivotal Fortify HN01 study, including increased manufacturing and development costs.
  • Consistent with the first quarter, we anticipate continued increases in operating expenses for 2026, reflecting increased investment in our clinical operations, particularly for the pivotal Fortify HNL1 study, with the interim analysis expected in mid-2027 and parallel study.
Read full transcript analysis ›